Research programme: proteasome inhibitors - Takeda Oncology
Latest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Harvard University
- Class
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 14 May 2008 Millennium Pharmaceuticals has been acquired by Takeda
- 15 Dec 1997 Preclinical development for Malaria in USA (Unknown route)